113 related articles for article (PubMed ID: 36016838)
1. Surveillance of adverse events associated with 145 000 doses of COVID-19 vaccines in a Brazilian municipality.
Martins-Filho PR; Santana RRR; Cavalcante TF; Barboza WS; de Souza MF; Góes MAO; Fontes ÂMB; da Silva MEL; Tanajura DM
Rev Panam Salud Publica; 2022; 46():e110. PubMed ID: 36016838
[TBL] [Abstract][Full Text] [Related]
2. Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature.
Eslait-Olaciregui S; Llinás-Caballero K; Patiño-Manjarrés D; Urbina-Ariza T; Cediel-Becerra JF; Domínguez-Domínguez CA
Ther Adv Drug Saf; 2023; 14():20420986231165674. PubMed ID: 37223456
[TBL] [Abstract][Full Text] [Related]
3. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais.
Silva RBD; Silva TPRD; Sato APS; Lana FCF; Gusmão JD; Souza JFA; Matozinhos FP
Rev Saude Publica; 2021; 55():66. PubMed ID: 34706042
[TBL] [Abstract][Full Text] [Related]
4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
5. High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil.
Alencar CH; Cavalcanti LPG; Almeida MM; Barbosa PPL; Cavalcante KKS; Melo DN; de Brito Alves BCF; Heukelbach J
Trop Med Infect Dis; 2021 Jul; 6(3):. PubMed ID: 34287384
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study.
Bernardi FF; Mascolo A; Sarno M; Capoluongo N; Trama U; Ruggiero R; Sportiello L; Fusco GM; Bisogno M; Coscioni E; Iervolino A; Di Micco P; Capuano A; Perrella A
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896978
[TBL] [Abstract][Full Text] [Related]
7. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
9. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
Yoon D; Kim JH; Lee H; Shin JY
Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Analysis of a Self-Reported Adverse Events Analysis after Receiving One of the Available SARS-CoV-2 Vaccine Schemes in Ecuador.
Ortiz-Prado E; Izquierdo-Condoy JS; Fernandez-Naranjo R; Simbaña-Rivera K; Vásconez-González J; Naranjo EPL; Cordovez S; Coronel B; Delgado-Moreira K; Jimbo-Sotomayor R
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891211
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
Ogar CK; Quick J; Gilbert HN; Vreman RA; Mantel-Teeuwisse AK; Mugunga JC
Drug Saf; 2023 Apr; 46(4):357-370. PubMed ID: 36811813
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological Evaluation of Events Allegedly Attributable to COVID-19 Vaccination: A Cross-Sectional Study in the Brazilian Amazon.
Silva MSO; Sotelo GM; Fernandes FP; Valentim LA; Paula MS; Quaresma TC; Dias MJDR; Esquerdo GAM; Moraes WP; Oliveira SMS
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543090
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
Front Immunol; 2021; 12():669010. PubMed ID: 34093567
[TBL] [Abstract][Full Text] [Related]
15. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
Jeon M; Kim J; Oh CE; Lee JY
J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects following COVID-19 vaccination in Iran.
Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Evaluation of Self-Reported Adverse Events Following Immunization with Different COVID-19 Vaccines in Türkiye.
Büyüker SM; Sultana A; Chowdhury JA; Chowdhury AA; Kabir S; Amran MS
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851193
[TBL] [Abstract][Full Text] [Related]
18. The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
Farias JP; da Silva PS; Fogaça MMC; Santana IVR; Luiz WB; Birbrair A; Amorim JH
J Virol; 2022 Apr; 96(8):e0017722. PubMed ID: 35389263
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.
Tobaiqy M; MacLure K; Elkout H; Stewart D
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835256
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
Alao MA; Ogunbosi BO; Ibrahim OR; Oladokun RE; Lagunju IA
Niger Med J; 2022; 63(3):248-258. PubMed ID: 38835530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
